title: Transurethral water-induced thermotherapy for the treatment of benign prostatic hyperplasia: a prospective multicenter clinical trial.
abstract: OBJECTIVE
  We evaluate the effectiveness and safety of transurethral water-induced thermotherapy for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH).
  
  
  METHODS
  A total of 125 patients with lower urinary tract symptoms due to BPH were enrolled at 8 study centers. Pretreatment evaluation included determination of International Prostate Symptom Score (I-PSS), peak urinary flow rate and quality of life score. Patients also completed a sexual function questionnaire. Patients were evaluated 3, 6 and 12 months after water-induced thermotherapy.
  
  
  RESULTS
  Significant improvements in I-PSS, peak urinary flow rate and quality of life score were observed as early as 3 months after water-induced thermotherapy. At 12 months I-PSS had improved by a median of 12.5 (95% confidence interval 11.5 to 13.5) versus baseline, peak urinary flow rate by 6.4 ml. per second (5.6 to 7.5) and quality of life score by 2.5 (2.0 to 2.5). I-PSS, peak urinary flow rate and quality of life score improved by 50% or more at 12 months in 61.5%, 71.3% and 71.6% of patients, respectively. No adverse impact of water-induced thermotherapy on sexual function was noted, and preexisting discomfort during ejaculation and interference in sexual function due to lower urinary tract symptoms were significantly ameliorated after treatment. Serious adverse events were infrequent and manageable.
  
  
  CONCLUSIONS
  Water-induced thermotherapy significantly alleviates lower urinary tract symptoms of BPH, increases peak urinary flow rate and enhances patient quality of life. This novel catheter based, minimally invasive treatment is easily administered in the outpatient setting. Water-induced thermotherapy holds promise as a useful and cost-effective option for the clinical management of BPH.
authors.affiliation: Diakoniekrankenhaus Rotenburg, Rotenburg, Department of Urology, Klinikum Grosshadern, Munich, Borken and Heilbronn, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Muschter
authors.forename: I
authors.initials: I
authors.lastname: Schorsch
authors.forename: L
authors.initials: L
authors.lastname: Danielli
authors.forename: C
authors.initials: C
authors.lastname: Russel
authors.forename: A
authors.initials: A
authors.lastname: Timoney
authors.forename: D
authors.initials: D
authors.lastname: Yachia
authors.forename: E
authors.initials: E
authors.lastname: Jolkowsky
authors.forename: G
authors.initials: G
authors.lastname: Matalon
authors.forename: T
authors.initials: T
authors.lastname: Roder
authors.forename: J
authors.initials: J
authors.lastname: Nordling
mesh_terms: D000368:Aged; D002404:Catheterization; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D016015:Logistic Models; D008297:Male; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000628:therapy*; D011788:Quality of Life; D016896:Treatment Outcome; D014867:Water
chemical_list: D014867:Water